España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Karyopharm Therapeutics
KPTI
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.7145
0.01
2.06%
Pre-Market: 5:34 PM EDT
Get Report
Comment
Karyopharm Therapeutics (KPTI) Forecast
News
Earnings
Karyopharm Therapeutics (KPTI) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Karyopharm Therapeutics (NASDAQ:KPTI) Stock
Karyopharm Therapeutics Stock (NASDAQ: KPTI)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, December 16, 2024
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
Tuesday, December 03, 2024
Karyopharm Therapeutics Will Update On Endome...
Benzinga Newsdesk
Wednesday, November 06, 2024
Piper Sandler Maintains Overweight on Karyoph...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Karyoph...
Benzinga Newsdesk
Tuesday, November 05, 2024
Karyopharm Expects 2024 Sales Of $145M-$155M ...
Benzinga Newsdesk
Karyopharm Therapeutics Q3 2024 GAAP EPS $(0....
Benzinga Newsdesk
Friday, November 01, 2024
HC Wainwright & Co. Reiterates Buy on Karyoph...
Benzinga Newsdesk
Thursday, October 31, 2024
Karyopharm Therapeutics shares are trading hi...
Benzinga Newsdesk
Karyopharm Therapeutics Announced That, Follo...
Benzinga Newsdesk
Monday, September 30, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
Thursday, September 05, 2024
Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround
Zacks
Wednesday, August 07, 2024
HC Wainwright & Co. Reiterates Buy on Karyoph...
Benzinga Newsdesk
RBC Capital Reiterates Outperform on Karyopha...
Benzinga Newsdesk
Baird Maintains Outperform on Karyopharm Ther...
Benzinga Newsdesk
Tuesday, August 06, 2024
Karyopharm Revises FY24 Total Revenue Outlook...
Benzinga Newsdesk
Karyopharm Therapeutics Q2 2024 GAAP EPS $(0....
Benzinga Newsdesk
Friday, June 28, 2024
HC Wainwright & Co. Maintains Buy on Karyopha...
Benzinga Newsdesk
Monday, June 03, 2024
HC Wainwright & Co. Reiterates Buy on Karyoph...
Benzinga Newsdesk
Sunday, June 02, 2024
Karyopharm On Saturday, Presented Updated Exp...
Charles Gross
Thursday, May 30, 2024
Karyopharm Therapeutics Files For Shelf Regis...
Benzinga Newsdesk
Thursday, May 09, 2024
HC Wainwright & Co. Reiterates Buy on Karyoph...
Benzinga Newsdesk
Wednesday, May 08, 2024
Karyopharm Announces Refinancing Transactions...
Benzinga Newsdesk
Karyopharm Therapeutics Reaffirms 2024 Revenu...
Benzinga Newsdesk
Karyopharm Therapeutics Q1 2024 GAAP EPS $(0....
Benzinga Newsdesk
Wednesday, April 24, 2024
Karyopharm Announces Presentations In Endomet...
Benzinga Newsdesk
Wednesday, March 13, 2024
Onco360 Selected As The Preferred National Sp...
Benzinga Newsdesk
Friday, March 01, 2024
HC Wainwright & Co. Maintains Buy on Karyopha...
Benzinga Newsdesk
Thursday, February 29, 2024
Karyopharm Sees 2024 Total Revenue $140M-$160...
Benzinga Newsdesk
Karyopharm Therapeutics Q4 2023 GAAP EPS $(0....
Benzinga Newsdesk
Earnings Scheduled For February 29, 2024
Benzinga Insights
Wednesday, February 28, 2024
Karyopharm Therapeutics's Earnings: A Preview
Benzinga Insights
Tuesday, February 06, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
Monday, February 05, 2024
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
Watching Karyopharm Therapeutics; Traders Cir...
Benzinga Newsdesk
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
Wednesday, January 31, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
Monday, January 08, 2024
Karyopharm Expects Preliminary Unaudited Full...
Benzinga Newsdesk
Monday, December 11, 2023
Karyopharm Shares Data At ASH 2023 Showing St...
Benzinga Newsdesk
Monday, November 06, 2023
Karyopharm Therapeutics Announced The Present...
Benzinga Newsdesk
Friday, November 03, 2023
Piper Sandler Maintains Overweight on Karyoph...
Benzinga Newsdesk
RBC Capital Maintains Outperform on Karyophar...
Benzinga Newsdesk
Thursday, November 02, 2023
Karyopharm Maintains FY 2023 Revenue Guidanc...
Benzinga Newsdesk
Karyopharm Therapeutics Q3 EPS $(0.30) Misses...
Benzinga Newsdesk
Earnings Scheduled For November 2, 2023
Benzinga Insights
Wednesday, November 01, 2023
Earnings Preview For Karyopharm Therapeutics
Benzinga Insights
Monday, October 30, 2023
Karyopharm Therapeutics Announces Clinical Tr...
Benzinga Newsdesk
Tuesday, September 26, 2023
Karyopharm to Present Selinexor Data at 2023 ...
Benzinga Newsdesk
Friday, September 08, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
Wednesday, September 06, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
Friday, September 01, 2023
Board Member at Karyopharm Therapeutics Acquires Company Stock Options Worth 68,000 Shares
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
